Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spherix, a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, has reported revenues of $1.43m for the fiscal year ended 31 December 2010, compared to $1.36m for the same period in 2009.
Subscribe to our email newsletter
The company has posted net loss of $7.74m, or $0.43 loss per diluted share, as compared to net loss of $9.15m, or $0.62 loss per diluted share, for the year ago period.
Spherix’s loss from operations was $8.01m for the fiscal year ended 31 December 2010, compared to the loss from operations of $9.15m.
Spherix CEO Claire Kruger said they have begun a human clinical postprandial trial with Dtagatose in the treatment of high triglycerides and data from this human trial are expected to be announced in the fall of 2011.